Literature DB >> 807599

Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages.

H Y Reynolds, J A Kazmierowski, H H Newball.   

Abstract

These studies compared the ability of specific secretory IgA (sIgA) and IgG antibodies to promote phagocytosis of viable pseudomonas aeruginosa by human alveolar macrophages. Macrophages were obtained by lung lavage of normal adult smoker and nonsmoker volunteers and were maintained as in vitro cell monolayers. Both immune sIgA and IgG agglutinating antibodies were demonstrated to coat and opsonize viable bacteria, whereas similar nonimmune immunoglobulin preparations did not. When alveolar macrophages were challenged with viable opsonized 14C-labeled Pseudomonas IgG-reacted bacteria were ingested better and killed more readily than sIgA-opsonized organisms. Phagocytic responses were not significantly different between macrophages obtained from smokers and nonsmokers. Although sIgA and IgG antibodies can be found in respiratory secretions and both are undoubtedly important in pulmonary host defense, IgG opsonic antibody was superior in enhancing the uptake of Pseudomonas by in vitro-cultured alveolar macrophages. It may be the more important respiratory antibody for certain bacterial infections.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807599      PMCID: PMC436596          DOI: 10.1172/JCI108102

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Immunoglobulins and other proteins in commercial preparations of gamma globulin.

Authors:  D C Heiner; L Evans
Journal:  J Pediatr       Date:  1967-05       Impact factor: 4.406

Review 2.  Primary immunodeficiencies. Report of a World Health Organization Committee.

Authors:  H Fudenberg; R A Good; H C Goodman; W Hitzig; H G Kunkel; I M Roitt; F S Rosen; D S Rowe; M Seligmann; J R Soothill
Journal:  Pediatrics       Date:  1971-05       Impact factor: 7.124

3.  Structural units of canine serum and secretory immunoglobulin A.

Authors:  H Y Reynolds; J S Johnson
Journal:  Biochemistry       Date:  1971-07-20       Impact factor: 3.162

4.  The ultrastructure of alveolar macrophages from human cigarette smokers and nonsmokers.

Authors:  S A Pratt; M H Smith; A J Ladman; T N Finley
Journal:  Lab Invest       Date:  1971-05       Impact factor: 5.662

5.  A structural study of human exocrine IgA globulin.

Authors:  R W Newcomb; D Normansell; D R Stanworth
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

6.  Immunoglobulin production in bronchial mucosa and bronchial lymph nodes, particularly in cystic fibrosis of the pancreas.

Authors:  F J Martinez-Tello; D G Braun; W A Blanc
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

7.  The J. Burns Amberson Lecture--in defense of the lung.

Authors:  G M Green
Journal:  Am Rev Respir Dis       Date:  1970-11

8.  Immunoglobulins in the bronchial washings of patients with chronic obstructive pulmonary disease.

Authors:  G A Falk; A J Okinaka; G W Siskind
Journal:  Am Rev Respir Dis       Date:  1972-01

9.  Induction of aryl hydrocarbon hydroxylase in human pulmonary alveolar macrophages by cigarette smoking.

Authors:  E T Cantrell; G A Warr; D L Busbee; R R Martin
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

10.  The human secretory immunoglobulin system: immunohistoligical localization of gamma A, secretory "piece," and lactoferrin in normal human tissues.

Authors:  D R Tourville; R H Adler; J Bienenstock; T B Tomasi
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  44 in total

Review 1.  The structure and function of human IgA.

Authors:  M A Kerr
Journal:  Biochem J       Date:  1990-10-15       Impact factor: 3.857

2.  Pseudomonas aeruginosa immunotherapy.

Authors:  J E Pennington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

Review 3.  Mechanisms and Targeted Therapies for Pseudomonas aeruginosa Lung Infection.

Authors:  Colleen S Curran; Thomas Bolig; Parizad Torabi-Parizi
Journal:  Am J Respir Crit Care Med       Date:  2018-03-15       Impact factor: 21.405

4.  Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages.

Authors:  J L Battershill; D P Speert; R E Hancock
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

5.  Pseudomonas aeruginosa pili as ligands for nonopsonic phagocytosis by fibronectin-stimulated macrophages.

Authors:  N M Kelly; J L Kluftinger; B L Pasloske; W Paranchych; R E Hancock
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

6.  Antibacterial immunity of lower airways: local or localized?

Authors:  J Franĕk; J Libich; J Malina
Journal:  Folia Microbiol (Praha)       Date:  1985       Impact factor: 2.099

7.  Nonopsonic phagocytosis of strains of Pseudomonas aeruginosa from cystic fibrosis patients.

Authors:  D P Speert; F Eftekhar; M L Puterman
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

8.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

9.  Effect of alveolar macrophages on Toxoplasma gondii.

Authors:  F W Ryning; J S Remington
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

10.  Surface morphology and function of human pulmonary alveolar macrophages from smokers and non-smokers.

Authors:  M Ando; M Sugimoto; R Nishi; M Suga; S Horio; H Kohrogi; K Shimazu; S Araki
Journal:  Thorax       Date:  1984-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.